Japan-Based International Drug Developer Awards $1.6 Million Thorough QT Study to eResearchTechnology
June 21 2005 - 10:02AM
PR Newswire (US)
Japan-Based International Drug Developer Awards $1.6 Million
Thorough QT Study to eResearchTechnology Agreement with Growing
International Organization Signals Broad Adoption of ICH, E14
Guidance Across All ICH Regions PHILADELPHIA, June 21
/PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT),
(NASDAQ:ERES), a leading provider of centralized
electrocardiographic (ECG) collection and interpretation services,
announced today that it has been awarded a Thorough QT (T-QT) Study
valued at more than $1.6 million in cardiac safety monitoring and
services from the U.S. subsidiary of a leading Japan- based drug
developer for one of its compounds in clinical trials. eRT is
providing comprehensive support, including provision of digital 12-
lead ECG equipment designed to facilitate collection of cardiac
safety data that is subsequently provided to eRT for analysis. eRT
will perform digital collection, measurement, interpretation,
review, and distribution of cardiac safety data through its
EXPeRT(R) workflow enabled data handling technology, the first
solution in production that was designed explicitly to meet
emerging international regulatory guidance and technical standards.
"We are pleased at having been selected to perform T-QT Study
services for the sponsor of this important drug candidate," said
Scott Grisanti, senior vice president of business development and
chief marketing officer at eRT. "E14 has completed Step 4 of the
ICH process, which enables immediate implementation across all
three ICH regions -- United States, Europe and Japan -- and
facilitates harmonized Best Practices. This award illustrates rapid
adoption of finalized guidance by the international drug
development community." Based in Philadelphia, PA,
eResearchTechnology, Inc. (http://www.ert.com/) is a provider of
technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis. The company is a
market leader in providing centralized core-diagnostic
electrocardiographic (ECG) technology and services to evaluate
cardiac safety in clinical development. The company is also a
leader in providing technology and services to streamline the
clinical trials process by enabling its customers to automate the
collection, analysis, and distribution of clinical data in all
phases of clinical development. Statements included in this release
may constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the
company's ability to obtain new contracts and accurately estimate
net revenues due to variability in size, scope and duration of
projects, and internal issues in the sponsoring client. The sponsor
may cancel this agreement at its sole discretion. As a result,
actual results may differ materially from any financial outlooks
stated herein. Further information on potential factors that could
affect the company's financial results can be found in the
company's Reports on Forms 10-K and 10-Q filed with the Securities
and Exchange Commission. DATASOURCE: eResearchTechnology, Inc.
CONTACT: Joan Sterlacci of eResearchTechnology, Inc.,
+1-908-203-6473; or Matt Hayden of Hayden Communications,
+1-858-704-5065, for eRT Web site: http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024